These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15688405)

  • 1. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.
    Eskandarpour M; Kiaii S; Zhu C; Castro J; Sakko AJ; Hansson J
    Int J Cancer; 2005 May; 115(1):65-73. PubMed ID: 15688405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of activated c-Met with NRAS-mutated human melanomas.
    Chattopadhyay C; Ellerhorst JA; Ekmekcioglu S; Greene VR; Davies MA; Grimm EA
    Int J Cancer; 2012 Jul; 131(2):E56-65. PubMed ID: 22020736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro.
    Eskandarpour M; Huang F; Reeves KA; Clark E; Hansson J
    Int J Cancer; 2009 Jan; 124(1):16-26. PubMed ID: 18814281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting NRAS in melanoma.
    Kelleher FC; McArthur GA
    Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
    J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
    Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
    J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma.
    Ellerhorst JA; Ekmekcioglu S; Johnson MK; Cooke CP; Johnson MM; Grimm EA
    Oncogene; 2006 Jun; 25(28):3956-62. PubMed ID: 16474847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.
    Kwong LN; Costello JC; Liu H; Jiang S; Helms TL; Langsdorf AE; Jakubosky D; Genovese G; Muller FL; Jeong JH; Bender RP; Chu GC; Flaherty KT; Wargo JA; Collins JJ; Chin L
    Nat Med; 2012 Oct; 18(10):1503-10. PubMed ID: 22983396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
    Petti C; Molla A; Vegetti C; Ferrone S; Anichini A; Sensi M
    Cancer Res; 2006 Jul; 66(13):6503-11. PubMed ID: 16818621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of BRAF and NRAS mutations in uveal melanoma.
    Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
    Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IQGAP1 is an oncogenic target in canine melanoma.
    Lee BH; Neela PH; Kent MS; Zehnder AM
    PLoS One; 2017; 12(4):e0176370. PubMed ID: 28445541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
    Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
    Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
    Yeh AH; Bohula EA; Macaulay VM
    Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.
    Posch C; Cholewa BD; Vujic I; Sanlorenzo M; Ma J; Kim ST; Kleffel S; Schatton T; Rappersberger K; Gutteridge R; Ahmad N; Ortiz/Urda S
    J Invest Dermatol; 2015 Oct; 135(10):2475-2483. PubMed ID: 26016894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines.
    Greshock J; Nathanson K; Medina A; Ward MR; Herlyn M; Weber BL; Zaks TZ
    Genes Chromosomes Cancer; 2009 May; 48(5):419-28. PubMed ID: 19226609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
    Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
    Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
    Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.